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Controversies in Cardiovascular Research
The Meta-Analysis of Cell-Based Cardiac Studies (ACCRUE) consortium recently published the results 
of the first prospective individual patient data (IPD)–based 
meta-analysis that included 12 randomized clinical trials 
investigating 1-year outcomes in patients with recent ST-
segment–elevation myocardial infarction (STEMI), who re-
ceived intracoronary autologous stem and progenitor cells.1 
This IPD meta-analysis showed no effect of intracoronary 
autologous cell-based therapy on left ventricular function 
and clinical outcome in patients with recent STEMI. This 
contradicts some data from several small- or medium-sized 
single- and multicenter studies and multiple publication-
based meta-analyses involving clinical cardiac regenera-
tion in STEMI. Although de Jong et al2 recently reported no 
difference between the cell therapy and control groups if the 
left ventricular parameters were measured by cardiac mag-
netic resonance imaging (cMRI), and the clinical end points 
(adverse events) were not significantly different in most of the 
meta-analyses, the major question is, why publication-based 
meta-analyses were in agreement, reporting beneficial effects 
of autologous reparative cell therapy in recent STEMI, but 
the IPD-based meta-analysis reported a negative outcome.1 A 
thorough review of the data collection, statistics, and overall 
principles of meta-analyses may provide some answers and 
useful insights to interpret current findings.
Counterpoint, see p 1264 
Response by Martin-Rendon, see p 1263
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Abstract: In contrast to multiple publication-based meta-analyses involving clinical cardiac regeneration therapy 
in patients with recent myocardial infarction, a recently published meta-analysis based on individual patient 
data reported no effect of cell therapy on left ventricular function or clinical outcome. A comprehensive review 
of the data collection, statistics, and the overall principles of meta-analyses provides further clarification and 
explanation for this controversy. The advantages and pitfalls of different types of meta-analyses are reviewed 
here. Each meta-analysis approach has a place when pivotal clinical trials are lacking and sheds light on the 
magnitude of the treatment in a complex healthcare field.  (Circ Res. 2016;118:1254-1263. DOI: 10.1161/
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Summary of Aggregate and IPD Meta-Analyses 
of Studies Including Patients With Recent 
STEMI and Intracoronary Cell Therapy
A summary of the meta-analyses of randomized trials in pa-
tients with recent STEMI receiving intracoronary cell-based 
therapy is provided in Table 1, showing the results of the ef-
ficacy outcome parameters.1–21 The meta-analyses of clinical 
studies involving patients with chronic ischemic heart disease 
who received percutaneous intracoronary or intramyocardial 
or direct (during coronary artery bypass surgery) intramyo-
cardial cell-based therapy are listed in Online Table I and 
References I–V. The main results of the meta-analyses, in-
cluding all cardiac studies with cell-based therapy irrespective 
of randomization, cell type, or delivery mode, are provided 
in Online Table II and References VI–IX.19–21 The first analy-
sis of the ACCRUE database reported the outcome of patients 
with recent STEMI randomized to intracoronary cell-based 
versus placebo therapy; therefore, this review concentrates 
on the discordance between the actual ACCRUE data and the 
data from the meta-analyses listed in Table 1.
Heterogeneous Outcomes Regarding Left 
Ventricular Function and Remodeling in Meta-
Analyses
The cardiac efficacy end point of all meta-analyses was the change 
in ejection fraction (EF), and most of the meta-analyses also re-
ported changes in end-diastolic volume (EDV) and end-systolic 
volume (ESV). There have been heterogeneous outcomes regard-
ing left ventricular function and remodeling, expressed as changes 
in EF, EDV, and ESV in meta-analyses (Table 1). Aggregate data 
meta-analyses suggested that there was a benefit from cell-based 
therapy, based on significant increases in EF when compared with 
controls, whereas IPD analysis did not support this. There was a 
significant improvement in EF in 16 of the 17 meta-analyses of 
STEMI patients with cell therapy, and 10 of these analyses re-
ported a significant decrease in ESV with a parallel significant de-
crease in EDV in 4 studies (Table 1). Decreases in ESV and EDV 
have particular importance in the assessment of left ventricular 
systolic function and remodeling. However, as the EF is derived 
from the EDV and ESV, parallel changes in both these measures 
might lead to an unchanged or similar calculated EF value, which 
should be considered in left ventricular function outcome studies.
One of the 3 meta-analyses assessing EF changes by cMRI 
showed no significant difference between cell treated and con-
trol patients (Table 1).2 The ACCRUE did not include a subgroup 
analysis of EF measurement by cMRI, as significantly (P<0.001) 
more patients in the cell-treated group were evaluated using cMRI 
than the controls, because of 2:1 randomization of some included 
studies (eg, Myocardial Regeneration by Intracoronary Infusion 
of Selected Population of Stem Cells in Acute Myocardial 
Infarction [REGENT] Trial, Use of Adult Autologous Stem Cells 
in Treating People 2 to 3 Weeks After Having a Heart Attack 
[The LateTIME Study], Use of Adult Autologous Stem Cells in 
Treating People Who Have Had a Heart Attack [TIME], Swiss 
Multicenter Intracoronary Stem Cells Study in Acute Myocardial 
Infarction [SWISS-AMI]).1,22–25 cMRI was used to quantify left 
ventricular function in 7 of 12 studies included in the ACCRUE 
analysis, and 6 of the 7 reported no difference between the cell-
treatment and control groups on EF, EDV, and ESV (REGENT, 
LateTIME, TIME, SWISS-AMI, Cardiosphere-Derived 
Autologous Stem Cells to Reverse Ventricular Dysfunction 
[CADUCEUS], and Intracoronary Stem Cell Therapy in Patients 
With Acute Myocardial Infarction [SCAMI]).22–27 Nevertheless, 
the methods for evaluation of left ventricular function and remod-
eling parameters were inconsistent between the studies included 
in the ACCRUE, as mentioned in the original article.1
In contrast to the IPD approach, clinical and statistical het-
erogeneity was greater (≤92.2%)3 with aggregate data pooling 
in the standard meta-analytic approach, based on the calcula-
tion of mean difference in EF between the groups. According 
to the large variability between the studies included in the pub-
lication-based meta-analyses, a larger change in EDV (−4.6 
mL) or ESV (−4.47 mL) was not significant, which was in con-
trast to the much smaller but significant change (EDV of −0.18 
mL or ESV of −0.25 mL) reported in other publications.4,7,10,14 
Although intratrial variability may provide an explanation, the 
observed effect sizes raises the question of clinical relevance 
for the change in EDV and ESV in these reported ranges (−4.16 
to +1.2 mL and −7.4 to −0.25 mL, respectively).
An evaluation of the relationship between the sample size of 
the meta-analyses and the time sequence of publications dem-
onstrates a narrowing difference between cell-based treatment 
and control patients on changes in EF (Figure 1). The larger 
studies are more likely to be recent because of increasing num-
bers of individual studies being published. Larger meta-analyses 
included not only more patients but also more studies. There 
are profoundly different methodological and interpretative chal-
lenges between a meta-analysis consisting of 2000 patients from 
2 studies and 1 with 2000 subjects from 50 studies. This perspec-
tive is helpful when considering the relationship between effect 
size and sample size. Larger meta-analyses tend to show smaller 
but significant changes in effect sizes. Although the larger meta-
analyses may be associated with a smaller change in EF on aver-
age, increasing the number of studies (with growing variability 
between the separate nonsynchronized studies) in the larger me-
ta-analyses may enhance the background noise, making it harder 
to discern the signal (effect) identified by smaller homogeneous 
studies.28 Thus, both the number of studies and the sample size 
included in meta-analyses determine their importance.
Mortality and Adverse Events Paradox in 
Meta-Analyses
The clinical end point results of the meta-analyses are listed 
in Table 2. Apart from mortality, evaluation of clinical adverse 
Nonstandard Abbreviations and Acronyms
ACCRUE Meta-Analysis of Cell-Based Cardiac Studies
cMRI cardiac magnetic resonance imaging
EDV end-diastolic volume
EF ejection fraction
ESV end-systolic volume
IPD individual patient data
STEMI ST-segment–elevation myocardial infarction
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events in publication-based meta-analyses is difficult because 
the end points of the separate studies have heterogeneous defini-
tions. Approximately one third of trials included hospitalization 
as an adverse event as a part of the composite outcome measure, 
or some additional adverse outcome, such as implantation of an 
automatic implantable cardioverter defibrillator, which did not 
count as an event in other studies. Notwithstanding, publica-
tion-based meta-analyses pool studies with diverse primary end 
point definitions that report one clinical outcome as an adverse 
event, resulting in a high level of heterogeneity and inconsis-
tency between trials. This approach also leads to contradictory 
conclusions of the effect of cell therapy on mortality or com-
bined or separate adverse events, with significant effects in 1 
meta-analysis but not in another (Table 2).
It is not uncommon for different meta-analyses to have 
conflicting results. As with clinical trials that use different 
methodologies (eg, continuous end points versus dichotomous 
end points, different follow-up periods or imaging modalities), 
meta-analyses commonly have differences in their end points, 
outcome assessments, and conclusions. As long as the collec-
tion of studies or the methodologies of analyses are differ-
ent, we can anticipate that results from the meta-analyses will 
vary. A difference in results is more likely when the overall 
effect size, the primum movens of the meta-analyses is small 
with large confidence intervals. An exception is the only IPD 
meta-analysis of the ACCRUE, which included a large num-
ber of patients using predefined clinical events for all studies. 
This translated into highly consistent estimates with low or 
no heterogeneity for clinical outcomes analyses. In addition, 
IPD collection allows time-to-event data to be generated for 
estimating time-dependent event-free survival, which is com-
pletely impossible in a publication-based meta-analysis.
Another exception is the Cochrane database analyses, which 
pooled studies with the same definitions for adverse outcome, 
or measurement of EF at the same time point using the same 
imaging tool.5,11 Although this method seems to be the statisti-
cally most correct with the highest quality among publication-
based meta-analyses, such an approach leads to the reduction 
in the number of patients, in particular, in the subgroups. It 
also might be responsible for some surprising results, such as 
a lower long-term (12–60 months) restenosis rate (2.7% in the 
bone marrow mononuclear cell group in 4 studies) than short-
term (<12 months) restenosis rate (11.3% in the bone marrow 
mononuclear cell group) or a higher incidence of target vessel 
revascularization (11.9% in the bone marrow mononuclear cell 
group in 9 studies with <12-month follow-up and 14.3% in the 
bone marrow mononuclear cell group with long-term follow-
up) than restenosis rate after cell therapy or control treatment.11 
Furthermore, the continuous updating of the Cochrane database 
to include more studies with more patients (similar to other 
Table 1. List of Meta-Analyses of Studies Including Patients With Recent Acute Myocardial Infarction and Intracoronary Cell-
Based Regenerative Therapy; Efficacy in Terms of Left Ventricular Function and Remodeling
Meta-Analyses on Cardiac 
Cell-Based Therapies Year
Type of Meta-
Analysis
No. of 
Studies
Sample 
Size FUP, mo
EDV Changes, 
mL
ESV Changes, 
mL
EF 
Changes, %
If MRI, Changes 
in EF, %
Hristov et al3 2006 RCT-Pb 5 482 4–6 nr nr 4.21* nr
Lipinski et al4 2007 RCT-Pb 10 698 6 −4.6 −7.4* 3.0* nr
Martin-Rendon et al5 2008 RCT-Pb 13 811 3–6 −2.47 −4.74* 2.99* nr
Zhang et al6 2009 RCT-Pb 6 525 5 −0.15 n.a. 4.77* nr
Zhang et al7 2009 RCT-Pb 7 660 6 −0.15 −0.25* 4.04* Nr
Bai et al8 2010 RCT-Pb 10 814 6 nr Nr 3.79* Nr
Kuswardhani et al9 2011 RCT-Pb 10 906 4–60 −3.08* −5.52* 2.07* Nr
Takagi and Umemoto10 2011 RCT-Pb 15 877 nr −0.18* −0.35* 2.87* Nr
Clifford et al11 2012 RCT-Pb 33 1765 <12 −3.52* −4.47* 2.87* 1.78*
Zimmet et al12 2012 RCT-Pb 29 1830 3–6 −3.39* −3.51* 2.7* nr
Delewi et al13 2012 RCT-Pb 16 1641 3–6 nr nr 2.55* 0.16*
Chen et al14 2013 RCT-Pb 5 510 nr −2.29 −4.47 4.18* nr
Jeong et al15 2013 RCT-Pb 17 1072 3–6 −3.46 −4.98* 2.51* nr
de Jong et al2 2014 RCT-Pb 22 1513 6 −2.8 −4.05* 2.1* 0.13
Liu et al16 2014 RCT-Pb 8 262 6–24 0.69 −0.99 3.17* nr
Gyöngyösi et al1 2015 RCT-IPD 12 1275 12 1.2 0.4 0.96 nr
Cong et al17 2015 RCT-Pb 17 1318 12 −1.69 −3.92* 2.74* nr
Meta-analyses focusing on specific outcome, eg, imaging or long-term outcome or including patients with chronic ischemic heart diseases or cohort studies are 
excluded.18–21 Comments to Table 1: Bai et al8 divided the Meluzin study into 2 parts, the Bone Marrow Transfer to Enhance ST-Elevation Infarct Regeneration (BOOST) 
study included twice (with the 6- and 18-month results); Kuswardhani et al9 same studies with different FUPs or subgroups included as separate studies; Zimmet et 
al12 intracoronary cell therapy with/without granulocyte-colony stimulating factor pooled; Delewi et al13 summary data of subgroups included. EF indicates ejection 
fraction; EDV, end-diastolic volume; ESV, end-systolic volume; FUP, follow-up; IPD, individual patient data based; MRI, magnetic resonance imaging; nr, not reported; 
Pb, publication based; and RCT, randomized controlled trial.
*P<0.05.
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meta-analyses) leads to some contrasting results compared 
with the previous version of the meta-analysis.5,11 However, 
even if ACCRUE used prespecified dichotomous parameters, 
the imaging modalities for measuring the continuous parameter 
are different and may vary in any of the IPD-based databases, 
which is one major drawback of such data collection.
Heterogeneous Statements on the Results of 
Subgroup Analyses
One important but surprising finding of the ACCRUE IPD me-
ta-analysis was the similar EF improvement in both cell-based 
treatment and controls in the subgroup of patients with low 
baseline EF. Some cell therapy trials22,29,30 and meta-analyses12–14 
Figure 1. Association between the 
number of patients (sample size) 
and weighted mean difference in 
the left ventricular ejection fraction 
(EF) between cell-based treatment 
and controls in meta-analyses of 
intracoronary cell therapy in patients 
with recent acute myocardial infarction. 
A, Sample size (blue columns) and 
changes in EF from baseline to follow-
up (differences between cell-treated and 
controls; red columns). B, Correlation 
between sample size and mean difference 
in EF between cell-based treatment and 
control groups.
Table 2. Different Results of Meta-Analyses Are Reporting Mortality or Combined or Separate Adverse Events
Cell Therapy for Cardiac Repair
No. of 
Studies Sample Size FUP, mo Mortality
Combined Adverse 
Events
Separate Adverse Events 
Significant in Cell-Treated Group
Hristov et al3 5 482 6 nr nr
Lipinski et al4 10 698 6 Nonsignif. Nonsignif. Re-AMI lower
Martin-Rendon et al5 13 811 3–6 Nonsignif. Nonsignif.
Zhang et al6 6 525 5 nr Nonsignif.
Zhang et al7 7 660 6 Nonsignif. Nonsignif.
Bai et al8 10 814 6 nr nr
Kuswardhani et al9 10 906 4–60 Nonsignif. nr
Takagi and Umemoto10 15 877 nr nr nr
Clifford et al11 33 1765 < or >12 Signif. Nonsignif.
Zimmet et al12 29 1830 3–6 Nonsignif. Nonsignif. TVR lower
Delewi et al13 16 1641 3–6 nr Nr
Chen et al14 5 510 nr nr Nonsignif.
Jeong et al15 17 1072 3–6 nr nr
de Jong et al2 22 1513 6 Nonsignif. Nonsignif.
Liu et al16 8 262 6–24 Signif. Nonsignif. TVR higher
Gyöngyösi et al1 12 1275 12 Nonsignif. Nonsignif.
Cong et al17 17 1318 12 Nonsignif. nr
Gyöngyösi et al1 Meta-Analysis of Cell-Based Cardiac Studies (ACCRUE) individual patient data-based meta-analysis in contrast with all other publication-based 
meta-analyses. Re-AMI indicates reinfarction; FUP, follow-up; nonsignif, no significant benefit of cell therapy; nr, not reported; signif., significant benefit of cell therapy; 
and TVR, target vessel revascularization
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are in agreement that patients with lower EF benefit more from 
cell therapy than patients with higher baseline EF, in terms of a 
greater increase in the EF at follow-up. This is in contrast with 
the results of another study31 and meta-analyses.1,4 Conflicting 
statements describing the effect of time (time interval between 
STEMI and cell therapy/randomization) and the number of 
injected cells increase the uncertainty about the effect of cell 
therapy (Table 3). Nevertheless, an effect of a parameter on 
outcome may not be strongly convincing if significant in one 
meta-analysis but not in another.
Furthermore, as the EF increases continuously during the 
first year after STEMI under standardized treatment, a lower 
EF measured very early after STEMI attack is a priori associ-
ated with a greater increase in EF (Figure 2).32 Resolution of 
the myocardial stunning in the immediate postinfarct period can 
dramatically improve the left ventricular EF. Thus, the timing 
of when the baseline EF is measured both in cell-treated and 
control patients is critical for the correct interpretation of the 
EF improvement. Accordingly, patients in the placebo group 
with lower EF demonstrated a greater increase in the EF during 
the follow-up in the ACCRUE. The changes in EF in the sub-
groups of cell-treated patients with baseline EF <50%, <45%, 
or <40% were 4.1±9.9%, 4.5±9.8%, or 5.0±9.7%, respectively; 
these values were similar to the controls classified into the same 
subgroup categories (3.5±9.0%, 3.8±9.0%, or 4.1±9.6%, re-
spectively) in the ACCRUE.1 Although patients with cell-based 
treatment with lower EF at baseline have a greater increase in 
the EF (Figure 2), this is also true for the control group. Both 
randomization arms received the standard medical therapy, with 
additional cell-based treatment in 1 group. However, the mag-
nitude of the difference between the groups, which may be at-
tributed to the cell therapy itself, was not significant.
The meta-analyses pooled studies that used different meth-
ods for measuring EF, except for the Cochrane database.5,11 
Measurement of left ventricular function using various methods 
results in various normal values and measurement errors. The 
methodological error of measuring left ventricular EF is 2.97% 
to 3.56% for MRI and ≤7.4% for echocardiography, and the 
absolute value of EF is lower if measured by radionuclide im-
aging.33–35 In addition, the difference in EF between cell-based 
Table 3. Results of Subgroup Analyses in Different Meta-Analyses
Cell Therapy for Cardiac 
Repair No. of Studies Sample Size
Effect of Baseline EF 
on Increase in EF in 
Cell-Treated Group
Effect of Time From AMI to Cell 
Delivery on Increase in EF in 
Cell-Treated Group
Effect of no. of Delivered 
Cells on Increase in EF in 
Cell-Treated Group
Hristov et al3 5 482 nr nr nr
Lipinski et al4 10 698 Nonsignif. Nonsignif. Nonsignif.
Martin-Rendon et al5 13 811 nr Signif. signif.
Zhang et al6 6 525 nr nr nr
Zhang et al7 7 660 nr Signif. nr
Bai et al8 10 814 nr nr nr
Kuswardhani et al9 10 906 nr nr nr
Takagi and Umemoto10 15 877 nr nr nr
Clifford et al11 33 1765 nr Signif. Signif.
Zimmet et al12 29 1830 Signif. Signif. Signif.
Delewi et al13 16 1641 Signif. Nonsignif. Nonsignif.
Chen et al14 5 510 Signif. nr nr
Jeong et al15 17 1072 nr nr nr
de Jong et al2 22 1513 nr nr Nonsignif.
Liu et al16 8 262 nr nr nr
Gyöngyösi et al1 12 1275 Nonsignif. Nonsignif. Nonsignif.
Cong et al17 17 1318 nr nr nr
Gyöngyösi et al1 Meta-Analysis of Cell-Based Cardiac Studies (ACCRUE) individual patient data-based meta-analysis in contrast with all other publication-based meta-
analyses. AMI indicates acute myocardial infarction; EF, ejection fraction; Nonsignif., nonsignificant; nr, not reported; and Signif.; significant.
Figure 2. Increased ejection fraction (EF) under standard 
medical treatment for acute myocardial infarction (AMI). Note 
that the lower the baseline EF at randomization/cell treatment, 
the higher the increase in EF at the 1-year follow-up. Adapted 
from Engblom et al32 with permission of the publisher. Copyright 
©2009, Wolters Kluwer Health.
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treatment and controls is always lower when MRI is used versus 
echocardiography or contrast ventriculography.36 However, it is 
unclear whether a mean difference of 0.9% to 4% in the EF be-
tween cell therapy and controls is greater than the methodologi-
cal error and represents a real, clinically relevant improvement.
Bias of Meta-Analyses
Data Collection Bias of Aggregate Data Versus 
Prespecified Outcome Collection in IPD
One of the major pitfalls of meta-analyses is collection bias 
related to the inclusion of clinically heterogeneous studies. 
Publication-based meta-analyses can include all studies but 
because of nonunique definitions of the parameters, they have 
high, nearly inacceptable heterogeneity between trials. In con-
trast, the IPD meta-analysis (ie, ACCRUE) used predefined 
end points; therefore, the heterogeneity and inconsistency is 
low, ≈0% for adverse events. The IPD approach allowed anal-
ysis of the data according to the intention-to-treat principle. 
However, the IPD meta-analysis results depend strongly on the 
choice of included studies (which is based on the availability 
of IPDs) and international cooperation between investigators. 
Thus, the inclusion of a majority of negative trials without the 
possibility of balanced inclusion of positive trials results in 
a negative outcome. The ACCRUE included 12 studies with 
104 patients per group, in contrast with the nonparticipating 
19 studies with a mean of 46 patients per group.1 Participating 
in ACCRUE required an agreement between the principal 
investigators of the study and the ACCRUE data committee 
on the aim and objectives of the ACCRUE, and involvement 
should be approved by the institutional scientific and publi-
cation policy and local ethical committee. Furthermore, be-
cause of different definitions used in the original study and 
the ACCRUE database, unavoidable differences between the 
published summary and IPD may develop in regards to terms 
and the interpretation of the result. This is a vulnerable target 
for international critics and a major reason for not participat-
ing in an IPD-based meta-analysis.
The IPD-based meta-analysis focuses on the most impor-
tant parameters and keeping the database as simple as possible; 
as a result, drawbacks of this approach include the omission 
of some surrogate outcome parameters and a lack of data on 
subjective measures. Publication-based meta-analyses can 
evaluate all published parameters, such as different follow-up 
times,2,3,6,12 injected cell volume,5,11 infarct size,5,11 bone marrow 
aspiration in the control group,15 different cell types,5,11,16 details 
on cell preparation,17 quality of life scores,5 or any subjective 
or semiobjective parameter. Some of these data are evaluated 
even if they are only reported in a fraction of the collected tri-
als. For example, myocardial infarct size decreased by 3.51% 
(P=0.004; n=240 patients) in the study of Martin-Rendon et al5 
and by 1.9% (not significant; n=670 patients) in the study of 
Clifford et al11 if follow-up was <12 months,11 but the improve-
ment was 3.36% when studies with ≥12-month follow-up were 
selected (P=0.0021; n=353 patients in the bone marrow cell 
therapy groups compared with controls). Evaluating changes 
in the infarct size is particularly difficult because most of the 
studies did not assess baseline infarct size. Similarly, heteroge-
neous results have been published on changes in the wall mo-
tion score index: not significant if follow-up was <12 months 
(−0.06; P=0.17; n=747 patients) but significant in another 
meta-analysis (−0.06; P=0.002; n=793 patients), and with lon-
ger follow-up (≥12 months; −0.12; P=0.0042; n=279 patients; 
thus the statistics may be contradictory when including differ-
ent studies.).11,17 The incidences of cardiac arrhythmias were 
similar in subgroups of cell-treated and control patients.5,6 As 
mentioned in the ACCRUE paper, even if such data were col-
lected in IPD-based meta-analyses, data available for <50% of 
the patients may not represent the whole collective; therefore, 
these data were not assessed.
Using IPDs avoids data conflicts. In addition, the IPD-
based meta-analysis using original data is protected from 
publication errors or from duplicate publications caused by 
diverse subgroup analyses. Yet, a major problem of IPD analy-
sis remains the long and overwhelming effort needed for data 
collection and analysis if no financial support is available.
Analysis Bias
Meta-analyses that rely on published literature may report 
some inaccuracies in summarizing the results, as different 
studies provide data in various formats. An example of this 
is the statistical calculation of the benefit of cardiac cell ther-
apy required for forest plotting for each of the control and 
cell treatment groups that includes (1) sample size, (2) mean 
changes from baseline to follow-up, and (3) the SD of these 
changes (Figure 3). However, if a study does not publish the 
changes in EF, but instead only the baseline and follow-up 
EF, the recalculation of the mean change is flawed because 
the mean change should include individuals who have evalu-
ation at both baseline and follow-up. Thus, although this 
recalculation is based on widely accepted mathematical–
statistical formulas,37 it may result in a different mean±SD 
than the unpublished data available to the trial’s investiga-
tors. Approximately half of the cell-based cardiac regen-
eration studies do not report arithmetic means and SDs for 
the changes in continuous outcome parameters, such as EF. 
Consequently, virtual recalculated mean±SD of some stud-
ies are used in different meta-analyses (Table 4)2,20 (Online 
References X–XIX), which enter different numeric data for 
Figure 3. Schematic of a forest plot 
statistic for calculation of the mean 
difference in a continuous parameter 
between the treated and control groups. 
Note that a 10-fold larger study has less 
weight in the final results due to a larger 
SD. CI indicates confidence interval; and IV, 
inverse variance.
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the same study into the forest plot statistics and decrease pre-
cision in their overall estimate. The SDs are pivotal for com-
puting the statistical weights of the studies; therefore, such an 
approach can lead to biased conclusions, not assigning a real 
weight to the study, and ultimately masking the true statistical 
effect (Figure 3). Moreover, summary data are often present-
ed for the entire study population, even if paired baseline-
follow-up data are not available for all patients. In contrast to 
these approaches, the IPD-based meta-analysis (such as the 
ACCRUE) uses the original data, with the ultimate benefit 
of not needing virtual data calculation. Accordingly, no dif-
ference was found between the IPD-calculated changes in 
the mean and SD and the values of the original studies if the 
study published these parameters.
Some differences between the meta-analysis results can 
also be attributed to errors in the individual publications and 
meta-analyses. However, the current review does not address 
the discrepancies found in the individual studies or meta-anal-
yses. The aim of presentation of data in Table 4 is to show 
some examples of how different the numbers entered into the 
decisive forest plot statistics can be if they are recalculated.
Summary of the Advantages and Disadvantages 
of Different Types of Meta-Analyses of Cell-
Based Cardiac Studies
Currently, several types of meta-analyses have been conducted 
to analyze the effect of cell therapy in ischemic heart disease 
(Table 5). There are different high-quality meta-analyses with 
Table 4. Examples of Reported Changes (Mean±SD) of Left Ventricular EF From Baseline to Follow-Up in the Original Publications 
(†), Compared With the Recalculated Values in the Publications of Jeevananthan et al20 (‡) and de Jong et al2 (§)
Intracoronary Cell Injection 
Study
Reported 
Changes in 
EF, %
Reported 
Changes in 
EF, %
Calculated 
Changes in 
EF, %
Calculated 
Changes in 
EF, %
Calculated 
Changes in 
EF, %
Calculated 
Changes in 
EF, %
Calculated 
Changes in 
EF, %
Calculated 
Changes in 
EF, %
Original 
Publication, 
Mean±SD
Original 
Publication, 
Mean±SD
Jeevananthan 
et al,20 
Mean±SD
Jeevananthan 
et al,20 
Mean±SD
Jeevananthan 
et al20
de Jong 
et al,2 
Mean±SD
de Jong 
et al,2 
Mean±SD de Jong et al2
Cell Treated Controls Cell Treated Controls
Weight of Study 
in Forest Plot Cell Treated Controls
Weight of Study 
in Forest Plot
Ge (Online Reference X 4.8+* −1.9+† 4.8±9.6*‡  −1.9±5.9‡ 1.3‡ 4.8±5.2*§ 3.5±1.9§ 4.8§
Penicka (Online Reference XI) 15.4+* 20.5+† 15.4±5.5*‡ 20.5±4.6‡ 2.1‡ 6±5*§ 8±4.8§ 4.4§
Meluzin (Online Reference XII) 3±1 and 
5±1++*
2±1† 4.0±4.7*‡ 2.0±4.7‡ 2.6‡ 5±6.6*§ 0±8.9§ 4.1§
Nogueira (Online Reference XIII) nr* nr† 6.9±6.2*‡ 2±11‡ 0.9‡ 6.7±5.5*§ 2±11.5§ 1.7§
Plewka (Online Reference XIV) 10±9* 5±8† 9±7*‡ 5±3.6§ 2.5‡ 9±5.8*§ 5±4.9§ 5.2§
Cao (Online Reference XV) nr* nr† 11.5±3.2*‡ 7.9±3.4‡ 2.9‡ 9.4±1.8*§ 7.1±2.6§ 6.5§
Yao (Online Reference XVI) 7.2±1.6 and 
11.7±2.6++*
2.9±2† 9.8±3.5*‡ 3.0±2.3‡ 2.8‡ 6.2±2.4*§ 2.2±1.8§ 6.3§
Grajek (Online Reference XVII) nr* nr† −3.4±5.9*‡ −6.4±7.9‡ 1.9‡ −2.5±5.6*§ 0±7.8§ 4.0§
Piepoli (Online Reference XVIII) 13.1±1.9* 5.3±2† 9.5±2.6*‡ 3.5±2.9‡ 2.8‡ 8.4±9.2*§ 2.2±12.6§ 2.5§
Hirsch (Online Reference XIX) 3.8±7.4 and 
4.2±6.2++*
4.0±5.8† … … … 3.8±7.4*§ 5.2±5.8§ 5.7§
Note the disparities between the original publications and recalculated values of both meta-analyses. +SD of mean not reported, ++ 2 different cell-treatment arms; 
nr, mean changes ± SD not reported (only baseline and follow-up absolute values are reported). Weight of the here selected (not all) studies from total 36 studies in the 
meta-analysis of Jeevanantham et al20 and 22 studies in the meta-analysis of de Jong et al.2 EF indicates ejection fraction; and nr, not reported.
Table 5. Types of Meta-Analyses in Cell-Based Cardiac Regeneration
Meta-Analysis Example Type Analysis Type Advantage Disadvantage
Pooling all studies Jeevananthan 
et al20
RCT-Pb All studies analyzed as 
one collective
Large sample size Large heterogeneity, 
missing data recalculated
Pooling certain studies with 
predefined inclusion criteria
Clifford et al11 RCT-Pb Different studies in 
subgroups
Large sample size, but 
lower number of patients in 
subgroups
Less heterogeneity, 
missing data recalculated
Pooling certain studies with 
predefined inclusion criteria
Delewi et al13 RCT-Pb, summary of 
mean of subgroups
Different studies in 
subgroups
Large sample size, but 
lower number of patients in 
subgroups
Less heterogeneity, 
missing data recalculated
Pooling certain studies with 
predefined inclusion criteria
Gyöngyösi et al1 RCT-IPD All patients and studies 
analyzed as one collective
Low heterogeneity, original 
data in database
Lower number of patients 
and studies
IPD indicates individual patient data based; Pb, publication based; and RCT, randomized controlled studies.
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specific aims and outcome measures, delivering different mes-
sages, and all have their advantages and disadvantages regarding 
the differences in analysis methodology, bias in data collection 
and study inclusion. All individual studies included ≤204 pa-
tients, so respective meta-analyses must pool small- and me-
dium-sized clinical trials with nonuniform designs, cell types, 
delivery modes, and follow-up times. Consequently, there is a 
lack of homogeneity. In addition, the trials used cell therapy at 
different times after the ischemic event and had diverse inclu-
sion or exclusion criteria. Even if the collection of IPD for me-
ta-analyses is regarded as the gold standard,37 no meta- analysis 
approach can replace randomized multicenter blinded studies.
Pitfalls of Evidence-Based Medicine: Negative 
Outcome of a Randomized Clinical Study 
Based on Positive Meta-Analysis Results
It has already been acknowledged that the results of meta-
analyses can differ from subsequent large randomized clini-
cal trials.38,39 The quality of publication-based meta-analyses 
depends on the quality, outcome assessment, and statistical 
report of the included clinical studies. Because of the variable 
precision of meta-analyses, the observed effect could be over-
estimated. Positive meta-analysis results can pave the way to 
initiating a large randomized clinical study with a neutral or 
negative outcome, as has been observed several times in medi-
cal literature and practice.38,39
Large randomized trials are considered the gold standard 
with the highest quality level I evidence for application of the 
study results in clinical practice based on the evidence-based 
medicine grading system. Importantly, the prespecified data 
collected in IPD-based meta-analyses (eg, ACCRUE) allow 
the results to truly reflect the original data, as well as pool 
them in a database in similar form as clinical trial case reports. 
Thus, IPD collection may be considered a novel prospective 
multicenter large randomized clinical trial and the IPD meta-
analyses as evidence-based medicine.
Conclusions
The IPD meta-analysis is currently considered the gold stan-
dard for meta-analyses assessing the impact of a treatment 
on clinical outcomes, especially in the case of small- and 
medium-sized clinical cardiac regeneration studies. An IPD 
approach, such as the ACCRUE, permits data verification and 
allows adjustment for the same variables across studies. When 
dealing with cardiovascular outcomes, this approach gener-
ates time-to-event data for estimating survival, can explore 
heterogeneity at the patient level, and allows subgroup analy-
ses. Using prespecified terms and conditions, the database is 
similar to that of a prospective multicenter randomized clinical 
trial with similar statistical assessment modalities combined 
with standardized approaches to evaluating meta-analyses.
Although data based on individual patients, rather than 
summary measures across patients, are preferable, these data 
are commonly unavailable. The IPD analyses rely on the data 
being available from studies. The IPD database is kept simple; 
therefore, a meta-analysis cannot evaluate some surrogate pa-
rameters if data are not gathered or factors are not available, 
such as different quality of life assessment scores.
The difficulties of the standard meta-analysis approaches 
have been reviewed here. Each has a place in the analysis of 
data when pivotal clinical trials are not available and each 
sheds light on the magnitude of the treatment effect in a com-
plex healthcare field.
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These 2 controversy articles attempt to explain why meta-anal-
yses on cardiac cell-based regenerative studies report differing 
results. They provide a comprehensive review of the literature 
in the field at the present time. I think controversies in any field 
could have a very positive outcome, and I sincerely hope that this 
is the case for cell therapies in cardiac regeneration. 
Noticeably, most of the controversies in the field stems from 
the lack of available data from a large, randomized, multicenter, 
blinded clinical trial and the substantial heterogeneity among 
clinical and meta-analytical studies. However, no meta-analysis 
is a replacement for that trial and as for any surrogate; one has 
to be mindful of its limitations and the fact that a meta-analyt-
ical finding may not always predict the results of a larger trial 
accurately.
I agree with the authors of the companion article that individual 
patient data meta-analyses can translate into reducing heteroge-
neity for clinical outcome measures and allow time-to-event data 
to be generated. Although the time and effort required and the fi-
nancial costs of conducting an individual patient data meta-anal-
ysis can reduce their applicability in some cases. Here is where 
trial meta-analyses have their relevance. I have to emphasize that 
most established scientific knowledge is supported by a conver-
gence of evidence. Interestingly, emerging evidence provided by 
qualitative (1) and quantitative (2, 3) assessment of cardiac cell-
based regenerative studies suggests that patients who have had 
a recent myocardial infarction may not benefit from cell-based 
therapies over standard medical care. The question is whether 
other patients may benefit from these treatments. The Meta-
Analysis of Cell-Based Cardiac Studies (ACCRUE) consortium has 
paved the way to encourage more international cooperation in 
this field. It has open the doors to more controversies that hope-
fully will stimulate more passionate debate and generate new 
work, whether is to conduct larger trials or to embark on more 
individual patient data studies. International cooperation will be 
needed in both cases.
I have been able to contribute to this miniseries because of the 
generosity of Professor Mariann Gyöngyösi, on behalf of the 
ACCRUE consortium, who suggested my name to the Circulation 
Research editorial team. I would also like to take this opportunity 
to thank all scientists and clinicians who have worked with me 
over the years evaluating clinical data and to all investigators who 
shared their unpublished data with us. Without them, the support 
of the Systematic Review Initiative and the Cochrane Heart Group, 
my work would not have been possible.
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Online Table I. List of meta-analyses assessing randomized controlled trials and included patients with chronic ischemic heart disease  
 
Cell 
therapy 
for iCMP  Year 
Type 
of 
MA 
Nr of 
studies 
Sample 
size Diagnosis 
Cell delivery 
route 
FUP 
(months) Mortality 
Combined 
adverse 
events 
Changes 
in EDV 
(mL) 
Changes 
in ESV 
(mL) 
Changes 
in EF 
(%) 
Baseline 
EF effect 
on EF 
improve-
ment 
Changes 
in EF if 
MRI used 
XiaoS1 2014 RCT 20 784 iCMP 
with/without 
PCI/CABG 3-12 
if no 
additional 
revasc., 
signif. non-signif -7.85* -9.75* 3.22* signif nr 
Kandala S2  2013 RCT 10 519 iCMP 
ic/im percut/ 
im CABG 3-18 signif nr -16.71* -20.64* 4.48* signif signif 
Zhu S3  2015 RCT 11 635 iCMP 
im 
percut/CABG 6-12 signif nr -4.73 -9.67* 2.57* non-signif nr 
Fischer S4  2013 RCT 9 649 iCMP 
ic/im percut/ 
im CABG 6-12 signif nr nr nr 3.47* nr nr 
TianS5  2014 RCT 11 492 iCMP 
im 
percut/CABG 3-12 nr nr -7.82 -10.66* 4.91* non-signif non-signif 
* p<0.05  
iCMP indicates ischemic cardiomyopathy; MA, meta-analysis; Nr, number; FUP, follow-up; EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection 
fraction; MRI, magnetic resonance imaging; RCT, randomized controlled trial; PCI, percutaneous coronary intervention; CABG, coronary artery bypass surgery;  ic, 
intracoronary; im, intramyocardial; percut, percutaneous; revasc, revascularization; signif, significant; nr, not reported; non-signif, non-significant. 
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Online Table II. List of meta-analyses assessing randomized and cohort trials and included patients with recent acute myocardial infarction and chronic 
ischemic heart disease  
 
Cell therapy 
for 
iCMP/AMI  Year 
Type of 
MA 
Nr of 
studies 
Sample 
size Diagnosis 
Cell 
delivery 
route 
FUP 
(months) Mortality 
Combined 
adverse 
events 
Changes 
in EDV 
(mL) 
Changes 
in ESV 
(mL) 
Changes 
in EF 
(%) 
Baseline 
EF effect 
on EF 
improve-
ment 
Changes 
in EF if 
MRI used 
Abdel-LatifS6 2007 
RCT+ 
cohort 
studies 18 999 
AMI, 
iCMP 
ic/im 
percut, im 
CABG   3-18 nr nr   -1.92  -4.8*  3.66* nr nr 
JeevananthamS7  2012 
RCT+ 
cohort 
studies 50 2625 
AMI, 
iCMP 
ic/im 
percut, im 
CABG   3-60 signif nr  -5.23*  -8.91* 3.96* non-signif non-signif 
SadatS8 2014 
RCT+ 
cohort 
studies 32 2406 
AMI, 
iCMP 
ic/im 
percut  3-61 nr nr nr nr 4.6±0.7* non-signif nr 
AfzalS9 2015 
RCT+ 
cohort 
studies 48 2602 
AMI, IHD, 
CIHD 
ic/im 
percut, im 
CABG   3-48 non-signif signif  -2.26  -6.37* 2.92* signif nr 
* p<0.05  
iCMP indicates ischemic cardiomyopathy; AMI, acute myocardial infarction; MA, meta-analysis; Nr, number; FUP, follow-up; EDV, end-diastolic volume; ESV, 
end-systolic volume; EF, ejection fraction; MRI, magnetic resonance imaging; RCT, randomized controlled trial; IHD, ischemic heart disease; CIHD, chronic 
ischemic heart disease; CABG, coronary artery bypass surgery; ic, intracoronary; im, intramyocardial; percut, percutaneous; signif, significant; nr, not reported; non-
signif, non-significant. 
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